S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Forecast & News

$13.45
-0.54 (-3.86 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$12.91
Now: $13.45
$14.00
50-Day Range
$10.28
MA: $12.33
$14.93
52-Week Range
$4.26
Now: $13.45
$15.65
Volume70,900 shs
Average Volume75,269 shs
Market Capitalization$203.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
CUSIPN/A
Phone858-900-2660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.75 million
Book Value$1.27 per share

Profitability

Net Income$-21,780,000.00

Miscellaneous

Employees72
Market Cap$203.61 million
Next Earnings Date3/11/2020 (Confirmed)
OptionableOptionable

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.


Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Ltd (NASDAQ:ARCT) announced its quarterly earnings data on Monday, May, 13th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.15. The biotechnology company had revenue of $4.35 million for the quarter, compared to analysts' expectations of $3.47 million. Arcturus Therapeutics had a negative net margin of 63.05% and a negative return on equity of 160.16%. View Arcturus Therapeutics' Earnings History.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Arcturus Therapeutics.

How can I listen to Arcturus Therapeutics' earnings call?

Arcturus Therapeutics will be holding an earnings conference call on Wednesday, March 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for ARCT?

5 analysts have issued 1 year price objectives for Arcturus Therapeutics' stock. Their forecasts range from $18.00 to $24.00. On average, they anticipate Arcturus Therapeutics' share price to reach $19.75 in the next twelve months. This suggests a possible upside of 46.8% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

What is the consensus analysts' recommendation for Arcturus Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

Has Arcturus Therapeutics been receiving favorable news coverage?

News coverage about ARCT stock has been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Arcturus Therapeutics.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a decrease in short interest in February. As of February 14th, there was short interest totalling 148,400 shares, a decrease of 5.8% from the January 30th total of 157,500 shares. Based on an average daily trading volume, of 74,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.8% of the company's stock are sold short. View Arcturus Therapeutics' Current Options Chain.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Energy Transfer LP Unit (ET), Corbus Pharmaceuticals (CRBP), KLA (KLAC), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Novavax (NVAX) and Viking Therapeutics (VKTX).

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the folowing people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)
  • Mr. Andrew H. Sassine, CFO & Director (Age 55)
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (9.14%), Dfpg Investments LLC (3.01%), Nikko Asset Management Americas Inc. (1.85%), Sumitomo Mitsui Trust Holdings Inc. (1.85%), Geode Capital Management LLC (0.56%) and Credit Suisse AG (0.39%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Institutional Ownership Trends for Arcturus Therapeutics.

Which major investors are selling Arcturus Therapeutics stock?

ARCT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., EAM Investors LLC, Renaissance Technologies LLC and Dfpg Investments LLC. View Insider Buying and Selling for Arcturus Therapeutics.

Which major investors are buying Arcturus Therapeutics stock?

ARCT stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Credit Suisse AG, Bank of Montreal Can, Acadian Asset Management LLC, Goldman Sachs Group Inc., Geode Capital Management LLC and Tower Research Capital LLC TRC . Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Insider Buying and Selling for Arcturus Therapeutics.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $13.45.

How big of a company is Arcturus Therapeutics?

Arcturus Therapeutics has a market capitalization of $203.61 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is http://www.arcturusrx.com/.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]


MarketBeat Community Rating for Arcturus Therapeutics (NASDAQ ARCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  345 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  659
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel